PADAGIS US Q1 2026 supplier risk profile: pharma importer, Israel-dependent, C-grade sourcing.
PADAGIS US imported 56 shipments in Q1 2026 across 3 suppliers sourced from 3 countries. Israel accounted for 96.4% of shipments, with PADAGIS ISRAEL PHARMACEUTICALS dominating at 54 shipments. The importer's single HS chapter classification (Chapter 13, plant extracts) reflects a narrow product focus, with one shipment of HS code 130219 arriving from UK supplier Ransom Naturals.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
PADAGIS US has no sanctions watchlist matches. No suppliers in the dataset register forced-labor exposure under UFLPA criteria. The importer's supply chain presents no identified compliance red flags at the current data depth.
3 distinct tier-1 suppliers in Q1 2026
| PADAGIS ISRAEL PHARMACEUTICALS | Israel | 54 |
| PADAGIS ISRAEL PHARMACEUTICALS | Spain | 1 |
| RANSOM NATURALS | United Kingdom | 1 |
Share of Q1 2026 inbound shipments by source country
5 tier-2 + 2 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.